Use fundamental data analysis to confirm all available indicators of Virtus LifeSci Biotech to find out if markets are presently mispricing the entity. We found ten available drivers for Virtus LifeSci Biotech Products ETF which can be compared to its competition. Please use Virtus LifeSci Price to Earning, Total Asset as well as the relationship between Total Asset and Equity Positions Weight to make a decision on weather Virtus LifeSci Biotech is priced fairly. Use Virtus LifeSci to enhance returns of your portfolios. The etf experiences unexpected upward trend. Watch out for market signals. Check odds of Virtus LifeSci to be traded at $48.98 in 30 days
Virtus LifeSci Biotech Products ETF is rated below average in net asset as compared to similar ETFs. It is rated below average in three year return as compared to similar ETFs . The ratio of Net Asset to Three Year Return for Virtus LifeSci Biotech Products ETF is about 3,301,024
Virtus LifeSci Biotech Systematic Risk
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Virtus LifeSci Biotech correlated with the market. If Beta is less than 0 Virtus LifeSci generally moves in the opposite direction as compared to the market. If Virtus LifeSci Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Virtus LifeSci Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Virtus LifeSci is generally in the same direction as the market. If Beta > 1 Virtus LifeSci moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
Virtus LifeSci Financial Distress Probability
Chance of Financial Distress
Virtus LifeSci Biotech Products ETF has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info